# ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

> **NCT00820079** · PHASE2 · COMPLETED · sponsor: **Addex Pharma S.A.** · enrollment: 120 (estimated)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** ADX10059
- **DRUG:** ADX10059 Matching Placebo

## Key facts

- **NCT ID:** NCT00820079
- **Lead sponsor:** Addex Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2009-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820079, "ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00820079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*